TXA-709 is a new type of antibiotic being developed by TAXIS Pharmaceuticals. The antibiotic specifically targets variants of the MRSA bacteria. TXA-709, a FtsZ-targeting benzamide prodrug, should be able to circumvent the problem of antibiotic resistance in certain bacterial infections by targeting previously neglected portions of these harmful microbes. Rather than formulating a slightly different … Continue reading Strategic Target Adjustment Revamps Antibiotic Development